1. ALLA AKTIER
  2. NYHETER
  3. MODUS THERAPEUTICS

Modus Therapeutics

Nyheter Modus Therapeutics Nyheter alla bolag

Annual General Meeting in Modus Therapeutics Holding AB (publ)

MARKN.

Today, the annual general meeting of 2023 was held in Modus Therapeutics Holding AB (publ). Below is a summary of the resolutions passed at the annual general meeting (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company’s website www.modustx.com).

Modus Therapeutics’ Annual General Meeting on 11 May 2023 resolved in accordance with the following:

  • That no dividend would be paid.
  • To discharge the board members and the managing director from liability with respect to their management of the company for the financial year 2022.
  • That the board of directors shall comprise three board members without any deputies.
  • To re-elect the board members Viktor Drvota, Ellen Donnelly and Torsten Goesch and to re-elect Viktor Drovta as the chairman of the board.
  • To re-elect Ernst & Young Aktiebolag as auditor.
  • To adopt principles for the Nomination Committee, in accordance with the Nomination Committee’s proposal.
  • To authorize the board, for a period that does not extend past the date of the next annual general meeting, on one or several occasions, with or without pre-emptive rights for the shareholders, to resolve on the issue of new shares, convertibles and/or warrants.
  • To approve a bridge financing facility of up to SEK 7 million from Karolinska Development.

For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se

About Modus Therapeutics and sevuparin
Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments
Annual General Meeting in Modus Therapeutics Holding AB (publ)

Datum 2023-05-11, kl 11:50
Källa MFN
Bifogade filer
Annual General Meeting in Modus Therapeutics Holding AB (publ)
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet